Lead Product(s): Human Alpha 1 Proteinase Inhibitor
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Glassia
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 07, 2021
Following the completion of the transition of GLASSIA manufacturing, Kamada will transfer the product’s us biologics license application (BLA) to takeda.
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RHB-204
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
RedHill recently initiated a Phase 3 study evaluating the safety and efficacy of RHB-204 as a first-line treatment for pulmonary NTM disease, to be conducted at up to 40 sites across the U.S.